MC
SMMT icon

Machina Capital’s Summit Therapeutics SMMT Stock Holding History

Machina Capital’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$800K Buy
54,875
+28,676
+109% +$509K 0.13% 216
2026
Q1 		$497K Buy
26,199
+14,563
+125% +$236K 0.1% 240
2025
Q4 		$204K Buy
+11,636
New +$219K 0.04% 333

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Machina Capital's SMMT Position: Q2 2026 in Review

Machina Capital increased its Summit Therapeutics (SMMT) stake by 109% in Q2 2026, buying an estimated $509K and bringing the position to 54,875 shares worth $800K. The position accounts for 0.13% of the portfolio, ranked #216.

Machina Capital first reported a position in SMMT in Q4 2025 and has held it in 3 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Machina Capital held 54,875 shares of Summit Therapeutics worth $800K as of Q2 2026.
  • Machina Capital bought 28,676 Summit Therapeutics shares in Q2 2026, an estimated $509K.
  • Summit Therapeutics made up 0.13% of Machina Capital's portfolio in Q2 2026, its #216 holding.
  • Machina Capital first reported a position in Summit Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Machina Capital's 13F filing for Q2 2026, filed 10 Aug 2026.